The present disclosure provides means of regenerating/restoring aged and/or damaged tissue or treating a medical condition by providing an extracorporeal circuit containing cells, including fibroblasts or dedifferentiated fibroblasts. that are in contact with plasma but not blood cells extracorporeally in a manner allowing for exchange of factors between a subject and an extracorporeally residing mass of cells. The disclosure provides means of titrating factors produced by the extracorporeal regenerative cell mass, thus allowing for a regenerative effect.

The present application relates to compositions and methods comprising polypeptides derived from MFG-E8 for treating and preventing fibrosis and other diseases.

Provided herein are compounds comprising peptides that bind Bfl-1. Also provided are compositions containing these peptides and methods of using such peptides in the treatment of cancer that include administering to a subject one of the peptides.

This disclosure provides peptide conjugates that are useful for inhibiting the progression of a hyperproliferative disorder, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, enhancing a response to a vaccine, or inhibiting the progression of a synucleinopathy.

Provided are methods of modulating the survival of therapeutic cells as well as cells and nucleic acids and vectors useful in such methods. Such survival modulation may include enhancing survival and/or enhancing death of the therapeutic cells. The provided methods include administering a therapeutic cell, nucleic acid and/or vector to a subject, the administered therapeutic cells, nucleic acids and/or vectors including one or more heterologous apoptosis modulating agents and/or one or more encoding sequences thereof. Cells of the disclosure include or encode one or more heterologous apoptosis modulating agents.

The present disclosure concerns genetically modified host cells that express an immunoproteasome in the absence of induction by or contact with a cytokine. The genetically modified stem cells are useful, for example, for vaccine production, and identification of new target antigens.

FMS-like tyrosine kinase 3L (FLT3L) fused to human cytokines, which find use in, e.g., cancer treatments, is described.

The present invention relates to interleukin-4 receptor-binding fusion proteins. More specifically, the invention provides, in part, fusion proteins that include an interleukin-4 or interleukin-13 protein moiety joined to an anti-apoptotic Bcl-2 family member protein moiety.

The present invention provides methods and compositions for stable genetic modification of immune cells. The genetic modifications can be used to produce immune cells for therapeutic or diagnostic purposes.

This disclosure provides peptide conjugates that are useful for inhibiting the progression of a hyperproliferative disorder, inhibiting the progression of sepsis, inhibiting the progression of an infectious disease, enhancing a response to a vaccine, or inhibiting the progression of a synucleinopathy.